{"id":"https://openalex.org/W4416630162","doi":"https://doi.org/10.1158/1078-0432.30709230","title":"Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia","display_name":"Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia","publication_year":2025,"publication_date":"2025-11-25","ids":{"openalex":"https://openalex.org/W4416630162","doi":"https://doi.org/10.1158/1078-0432.30709230"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.30709230","doi":"https://doi.org/10.1158/1078-0432.30709230","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30709230","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_Outcomes_in_Patients_with_High-Risk_Features_after_Fixed-Duration_Ibrutinib_plus_Venetoclax_Phase_II_CAPTIVATE_Study_in_First-Line_Chronic_Lymphocytic_Leukemia/30709230/1/files/59834046.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_Outcomes_in_Patients_with_High-Risk_Features_after_Fixed-Duration_Ibrutinib_plus_Venetoclax_Phase_II_CAPTIVATE_Study_in_First-Line_Chronic_Lymphocytic_Leukemia/30709230/1/files/59834046.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026842309","display_name":"John Nathan Allan","orcid":"https://orcid.org/0000-0002-2088-0899","observed_orcids":["https://orcid.org/0000-0002-2088-0899"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John N. Allan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2088-0899","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ian W. Flinn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6724-290X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005565037","display_name":"Tanya Siddiqi","orcid":"https://orcid.org/0000-0001-5292-8298","observed_orcids":["https://orcid.org/0000-0001-5292-8298"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tanya Siddiqi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5292-8298","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087770514","display_name":"Paolo Ghia","orcid":"https://orcid.org/0000-0003-3750-7342","observed_orcids":["https://orcid.org/0000-0003-3750-7342"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paolo Ghia","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3750-7342","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034517642","display_name":"Constantine Si Lun Tam","orcid":"https://orcid.org/0000-0002-9759-5017","observed_orcids":["https://orcid.org/0000-0002-9759-5017"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Constantine S. Tam","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9759-5017","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0064-4549","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055100327","display_name":"Paul M. Barr","orcid":"https://orcid.org/0000-0002-9733-401X","observed_orcids":["https://orcid.org/0000-0002-9733-401X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul M. Barr","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9733-401X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078620979","display_name":"Anna Elinder Camburn","orcid":"https://orcid.org/0000-0002-6097-7839","observed_orcids":["https://orcid.org/0000-0002-6097-7839"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Elinder Camburn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6097-7839","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008054206","display_name":"Alessandra Tedeschi","orcid":"https://orcid.org/0000-0001-8724-2771","observed_orcids":["https://orcid.org/0000-0001-8724-2771"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alessandra Tedeschi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8724-2771","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085393928","display_name":"Xavier Camille Albert Badoux","orcid":"https://orcid.org/0000-0001-9042-527X","observed_orcids":["https://orcid.org/0000-0001-9042-527X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xavier C. Badoux","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9042-527X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035890812","display_name":"Ryan W. Jacobs","orcid":"https://orcid.org/0000-0001-7814-7959","observed_orcids":["https://orcid.org/0000-0001-7814-7959"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ryan Jacobs","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7814-7959","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002467749","display_name":"Bryone Jean Kuss","orcid":"https://orcid.org/0000-0002-5811-1331","observed_orcids":["https://orcid.org/0000-0002-5811-1331"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bryone J. Kuss","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5811-1331","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013236194","display_name":"Livio Trentin","orcid":"https://orcid.org/0000-0003-1222-6149","observed_orcids":["https://orcid.org/0000-0003-1222-6149"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Livio Trentin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1222-6149","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053787554","display_name":"Cathy Zhou","orcid":"https://orcid.org/0000-0003-2406-1484","observed_orcids":["https://orcid.org/0000-0003-2406-1484"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cathy Zhou","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2406-1484","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109542836","display_name":"Anita Sz\u0151ke","orcid":"https://orcid.org/0000-0001-6975-7114","observed_orcids":["https://orcid.org/0000-0001-6975-7114"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anita Szoke","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6975-7114","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092111581","display_name":"Christopher Abbazio","orcid":"https://orcid.org/0000-0002-1917-7290","observed_orcids":["https://orcid.org/0000-0002-1917-7290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Abbazio","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1917-7290","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William G. Wierda","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7357-270X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.984000027179718},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":1.0},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9610000252723694},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7789999842643738},{"id":"https://openalex.org/keywords/fixed-duration-treatment","display_name":"fixed-duration treatment","score":0.7770000100135803},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8759999871253967},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.8090000152587891},{"id":"https://openalex.org/keywords/kaplan-meier-curves","display_name":"Kaplan-Meier curves","score":0.7149999737739563}],"concepts":[{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.9458000063896179},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8090999722480774},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.6969000101089478},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6626999974250793},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.6563000082969666},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5928999781608582},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.57669997215271},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.44589999318122864},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.42829999327659607},{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.39100000262260437},{"id":"https://openalex.org/C2781442060","wikidata":"https://www.wikidata.org/wiki/Q425745","display_name":"Bendamustine","level":4,"score":0.3815000057220459},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.37119999527931213},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.35030001401901245},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.31520000100135803},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.30329999327659607},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.29190000891685486},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.2736000120639801},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.26989999413490295},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.2669000029563904},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.2612000107765198},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.26080000400543213},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.251800000667572}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.30709230","doi":"https://doi.org/10.1158/1078-0432.30709230","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30709230","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_Outcomes_in_Patients_with_High-Risk_Features_after_Fixed-Duration_Ibrutinib_plus_Venetoclax_Phase_II_CAPTIVATE_Study_in_First-Line_Chronic_Lymphocytic_Leukemia/30709230/1/files/59834046.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30709230","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_Outcomes_in_Patients_with_High-Risk_Features_after_Fixed-Duration_Ibrutinib_plus_Venetoclax_Phase_II_CAPTIVATE_Study_in_First-Line_Chronic_Lymphocytic_Leukemia/30709230","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.30709230","doi":"https://doi.org/10.1158/1078-0432.30709230","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30709230","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_Outcomes_in_Patients_with_High-Risk_Features_after_Fixed-Duration_Ibrutinib_plus_Venetoclax_Phase_II_CAPTIVATE_Study_in_First-Line_Chronic_Lymphocytic_Leukemia/30709230/1/files/59834046.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4416630162.pdf","grobid_xml":"https://content.openalex.org/works/W4416630162.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4379598412","https://openalex.org/W4384300296","https://openalex.org/W4282964256","https://openalex.org/W4400109298","https://openalex.org/W4380085383","https://openalex.org/W4379281324","https://openalex.org/W4385667137","https://openalex.org/W4410819594","https://openalex.org/W4401878482","https://openalex.org/W4401876857"],"abstract_inverted_index":{"Supplementary":[0],"Figure":[1],"S1.":[2],"Kaplan-Meier":[3],"curves":[4],"of":[5,18],"progression-free":[6],"survival":[7,11],"(A)":[8],"and":[9,30],"overall":[10],"(B)":[12],"in":[13,26],"the":[14,27,31],"total":[15],"pooled":[16],"population":[17],"patients":[19],"treated":[20],"with":[21],"fixed-duration":[22],"ibrutinib":[23],"plus":[24],"venetoclax":[25],"FD":[28],"cohort":[29,33],"MRD":[32],"placebo":[34],"arm.":[35],"Tick":[36],"marks":[37],"indicate":[38],"censored":[39],"patients.":[40]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2025-11-25T00:00:00"}